Loading clinical trials...
Loading clinical trials...
Azacytidine-venetoclax Combination as Leukemia Debulking Treatment Followed by Reduced Toxicity Conditioning Regimen (Melphalan Busulfan and Fludarabine, MBF) as Salvage Therapy for Refractory Acute Myeloid Leukemia (AML).
Conditions
Interventions
Aza-Ven-allo-HSCT
Locations
3
China
Blood & Marrow Transplantation Center, RuiJin Hospital
Shanghai, China
Department of Hematology, Shanghai No6 Hospital
Shanghai, China
Shanghai ZhaXin Hospital
Shanghai, China
Start Date
January 1, 2021
Primary Completion Date
January 1, 2024
Completion Date
June 1, 2024
Last Updated
June 1, 2021
NCT06484062
NCT06763341
NCT06222580
NCT06177067
NCT06660368
NCT05143996
Lead Sponsor
Shanghai Jiao Tong University School of Medicine
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions